Sarepta's New Leadership
Sarepta Appoints Michael Severino as CEO, Tapping Biopharma Veteran to Lead Genetic Medicine Growth
Anonymous
Key Points
1
Severino's AbbVie tenure included involvement in the development and approvals of Rinvoq, Skyrizi, and Venclexta, illustrating his track record across oncology, immunology, and neuroscience and his ability to expand a major pipeline.
2
Sarepta's board chair Kathleen Behrens said Severino's scientific depth, strategic vision, and track record of execution were key factors in his appointment.
3
Earlier in his career, Severino held roles at Amgen, including Chief Medical Officer, giving him broad experience across biotechnology and drug development.
4
Doug Ingram's compensation for 2025 was disclosed as $1.2 million in salary, with total compensation of $7.8 million, according to public disclosure.
5
Severino described Sarepta as the leader in precision genetic medicine for rare diseases and expressed enthusiasm about joining a company driven by a purpose to bring innovative therapies and hope to patients and families facing serious diseases.
Sarepta Therapeutics named Michael Severino, M.D., as its new chief executive officer, effective July 28, 2026, the company announced. Severino, who brings more than 25 years of biopharmaceutical experience, takes over from Doug Ingram, who is retiring after leading the rare disease drugmaker for nearly a decade. STAT News reported the appointment, noting Severino's most recent role as CEO of Tessera Therapeutics.
Sarepta shares rose in premarket trading following the news. Ingram will stay on in an advisory capacity through the end of 2026 to help with the transition, according to MarketScreener.
Severino's Path From AbbVie to Sarepta
Before joining Sarepta, Severino served as vice chairman and president at AbbVie, one of the world's largest drugmakers. There, he led research and development and helped build out the company's drug pipeline. His tenure included work on Rinvoq, Skyrizi, and Venclexta — blockbuster drugs spanning immunology, oncology, and neuroscience. Earlier in his career, he held the role of Chief Medical Officer at Amgen, giving him experience across both large biotech and pharma.
Most recently, Severino was CEO of Tessera Therapeutics and a CEO-Partner at Flagship Pioneering, the life sciences venture firm. MarketScreener noted both roles highlighted his focus on next-generation genetic medicine — an area that aligns closely with Sarepta's core business.
Why Sarepta's Board Chose This Leader Now
Board chair Kathleen Behrens said Severino's "scientific depth, strategic vision, and track record of execution" were the deciding factors in his selection. Sarepta is a leader in precision genetic medicine, focused on rare diseases like Duchenne muscular dystrophy, or DMD — a severe muscle-wasting condition that mostly affects young boys. The company has built a pipeline of RNA-targeted therapies and gene treatments aimed at slowing or stopping the disease.
Severino called Sarepta "the leader in precision genetic medicine for rare diseases" and said he was eager to join a company driven by a "purpose to bring innovative therapies and hope to patients and families facing serious diseases." The appointment signals the board wants a leader with both deep science experience and a proven ability to bring drugs to market.
Doug Ingram Steps Down After Transforming Sarepta
Ingram's retirement ends a long run at the helm of Sarepta. In 2025, he earned a base salary of $1.2 million, with total compensation reaching $7.8 million, according to public disclosure. Under his leadership, Sarepta won approvals for multiple DMD therapies and became a key player in gene therapy. He will remain as an advisor through December 2026 to ensure a smooth handoff, STAT News reported.
What This Means for Sarepta's Drug Pipeline
Sarepta faces a competitive biotech landscape as it works to advance its next wave of treatments. The company is developing RNA-targeted therapies — drugs that work by switching genes on or off — as well as gene therapies for DMD. Bringing in a leader with Severino's background suggests the board wants to push these programs forward faster. MarketScreener noted the board change takes effect July 28, 2026, the same day Severino joins both as CEO and board member.
The positive market reaction — shares moving higher in premarket trading — shows investors welcomed the pick. With Severino's experience turning scientific research into approved drugs at AbbVie and Amgen, Sarepta is betting he can do the same for its next generation of rare disease medicines.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
18
Articles
91
Reach
109
A
AnonymousAuthor
